Nalmefene for Alcohol Use Disorder: How It Works, Dosage, Side Effects, and Alternatives

Nalmefene is a prescription opioid receptor antagonist approved in Europe under the brand name Selincro for reducing alcohol consumption in adults with alcohol use disorder.

Nalmefene is approved in the United States as Opvee for emergency opioid overdose reversal. It is not FDA-approved for alcohol dependence in the US, making it one of the more misunderstood medications in addiction pharmacology.

For people drinking at high-risk levels who are not seeking complete abstinence, nalmefene offers a harm-reduction approach that sets it apart from abstinence-oriented medications like disulfiram. It is taken as needed, not daily, making it the only opioid antagonist with an as-needed dosing protocol for alcohol use disorder.

Key Takeaways

• Nalmefene is not FDA-approved for alcohol use disorder in the United States. It is approved as Opvee for opioid overdose reversal only. In Europe it is marketed as Selincro for alcohol dependence.
• The standard European dosing protocol is 18 mg taken 1 to 2 hours before anticipated drinking, not on a fixed daily schedule, which distinguishes it from naltrexone.
• According to the World Health Organization, alcohol use disorder affects approximately 283 million people globally, underscoring the demand for pharmacological treatment options beyond the three currently FDA-approved agents.
• A 2014 randomized controlled trial by van den Brink et al. found that nalmefene reduced heavy drinking days by 3.2 days per month and decreased total alcohol consumption by 14.3 grams per day compared to placebo over 6 months.
• Nalmefene has no observed dose-dependent liver toxicity, a key pharmacokinetic advantage over naltrexone for patients with compromised hepatic function.

What Is Nalmefene and What Is It Used For?

Nalmefene is an opioid receptor modulator that reduces the brain’s reward response to alcohol by blocking the endorphin-mediated reinforcement mechanism triggered by drinking. It belongs to the same pharmacological class as naltrexone but carries a distinct receptor profile and pharmacokinetic properties that produce different clinical applications.

Approved Uses

In the United States, nalmefene is FDA-approved only as Opvee, a nasal spray formulation approved in May 2023 for emergency reversal of known or suspected opioid overdose in adults and adolescents aged 12 and older. It is not approved domestically for alcohol dependence treatment.

In Europe, the European Medicines Agency approved Selincro in December 2012 for reducing alcohol consumption in adults with alcohol use disorder (AUD) who drink at high-risk levels, defined as more than 60 grams per day for men and more than 40 grams per day for women. The approval requires concurrent psychosocial support through a structured counseling model.

Off-Label and Investigational Uses

• Behavioral addictions: Research published in the American Journal of Psychiatry investigated nalmefene for gambling disorder, with one trial reporting significant reductions in gambling urges and behavior compared to placebo.
• Opioid use disorder: The longer half-life of nalmefene compared to naloxone has generated research interest for opioid overdose reversal in settings where prolonged mu-opioid receptor blockade is clinically desirable.
• Discontinued indications: Oral nalmefene was investigated for pathological gambling, pruritus, rheumatoid arthritis, and smoking cessation, but development was discontinued for all of these indications.

How Nalmefene Works: Mechanism of Action

Nalmefene reduces alcohol consumption by disrupting the neurochemical reward chain that makes drinking pleasurable. When a person drinks, alcohol triggers endorphin release in the mesolimbic system. Those endorphins bind to mu-opioid and delta-opioid receptors, producing dopamine release in the nucleus accumbens and generating the reinforcing “feel-good” effect associated with alcohol.

Receptor Profile

Nalmefene acts as an inverse agonist at the mu-opioid receptor (Ki = 0.24 nM) and as a weak partial agonist at the kappa-opioid receptor (Ki = 0.083 nM). It also has antagonist activity at the delta-opioid receptor (Ki = 16 nM), though at lower affinity than its activity at mu and kappa sites.

This receptor profile directly distinguishes nalmefene from naltrexone:

Property	Nalmefene	Naltrexone
Mu-opioid receptor	Inverse agonist	Antagonist
Kappa-opioid receptor	Partial agonist	Antagonist
Half-life (oral)	10 to 13 hours	4 to 13 hours
Liver toxicity	None dose-dependent	Dose-dependent risk at high doses
Dosing schedule	As needed (1-2 hrs before drinking)	Daily fixed dose
FDA approval (AUD)	Not approved	Approved

The Dopamine Suppression Pathway

By blocking mu and delta receptors, nalmefene prevents alcohol-induced endorphin activation, which stops dopaminergic stimulation of the nucleus accumbens. This reduction in dopamine release weakens the pleasurable reinforcement signal that drives continued drinking. Over time, the learned association between alcohol consumption and reward is progressively weakened, reducing craving intensity.

The kappa-opioid receptor partial agonism adds a secondary mechanism. Kappa activation is associated with dysphoria and stress regulation. By partially activating kappa receptors, nalmefene may blunt the stress-driven craving that leads to relapse in individuals who drink to manage negative emotional states.

Nalmefene Dosage and Administration

The European Medicines Agency dosing protocol calls for one 18 mg tablet taken orally one to two hours before a situation where the patient anticipates alcohol consumption. This as-needed schedule is designed for harm reduction rather than abstinence.

Dosing Guidelines

• Dose: 18 mg (one tablet) taken 1 to 2 hours before drinking
• Maximum frequency: Once per day
• Schedule type: As needed, not fixed daily
• Concurrent requirement: Psychosocial support through the BRENDA program (Biopsychosocial evaluation, Report findings, Empathy, Needs identification, Direct advice, Assessment of patient’s Reaction)
• Target population: Adults with high-risk alcohol consumption who have not required immediate detoxification

Pharmacokinetics

Nalmefene is rapidly absorbed following oral administration. Brain mu-opioid receptor occupancy reaches 87 to 100% at peak plasma concentrations approximately 3 hours after oral dosing. At 26 hours post-administration, brain MOR occupancy remains 83 to 100%, demonstrating prolonged central receptor blockade relative to blood levels. The half-time of brain MOR occupancy is approximately 29 hours, substantially longer than naloxone.

Nalmefene Side Effects

Nalmefene produces a characteristic side effect profile that is primarily neurological and gastrointestinal. Most reactions are mild, occur during treatment initiation, and resolve within days to weeks.

Common Side Effects

Clinical trials report the following very common side effects (occurring in 10% or more of patients):

• Nausea: Most frequently reported, occurring in approximately 34% of participants. Typically peaks in the first week of treatment.
• Dizziness: Reported in approximately 19% of participants. Often associated with treatment initiation.
• Insomnia: Occurring in approximately 12.5% of participants, reflecting kappa-opioid receptor activation effects on sleep architecture.
• Headache: Moderate frequency, generally self-limiting.
• Fatigue: Reported in early treatment phases, resolving with continued use.

Severe and Psychiatric Side Effects

• Hallucinations and dissociation: Consistent with kappa-opioid receptor activation, which produces dysphoria and perceptual disturbances in susceptible individuals. The European Medicines Agency issued guidance that nalmefene should not be prescribed to patients with severe mental health disorders.
• Suicidal ideation: Reported in post-marketing surveillance and clinical trials. The EMA issued a warning to clinicians to monitor for suicidal thoughts, particularly in patients with depression.
• Psychiatric decompensation: Case reports document psychotic episodes in patients with pre-existing schizoaffective disorder and other psychotic conditions taking nalmefene.

Contraindications

Nalmefene is contraindicated in patients who:

• Currently use opioid medications (risk of precipitating acute opioid withdrawal)
• Have known hypersensitivity to nalmefene or any excipients
• Are pregnant or breastfeeding (animal studies showed adverse fetal effects)
• Have severe psychiatric disorders including psychosis, severe depression, or active suicidal ideation

Nalmefene vs. FDA-Approved AUD Medications

Because nalmefene is not FDA-approved for alcohol use disorder in the United States, clinicians treating alcohol use disorder in the US typically prescribe one of three FDA-approved medications. Each works through a different mechanism and suits a different treatment goal.

Nalmefene vs. Naltrexone

Naltrexone (Vivitrol as a monthly injectable, or Revia as a daily oral tablet) is FDA-approved for alcohol use disorder and works through the same mu-opioid receptor antagonism mechanism as nalmefene. The key differences are daily versus as-needed dosing, the absence of kappa partial agonism in naltrexone, and a dose-dependent liver toxicity risk with naltrexone that is absent with nalmefene. For patients with hepatic impairment, nalmefene’s pharmacokinetic profile may theoretically offer advantages, though clinical head-to-head trials comparing the two in this population are limited. Right Choice Recovery provides Vivitrol injections as part of its medication-assisted treatment program.

Nalmefene vs. Acamprosate

Acamprosate (Campral) modulates glutamate and GABA neurotransmission to restore neurochemical balance disrupted by chronic alcohol use. Unlike nalmefene and naltrexone, which reduce the reward of drinking, acamprosate is primarily used to maintain abstinence after detox by dampening the excitatory hyperactivity that drives protracted withdrawal craving. It is the preferred agent for patients who have already achieved abstinence and want to sustain it.

Nalmefene vs. Disulfiram

Disulfiram (Antabuse) inhibits aldehyde dehydrogenase, blocking alcohol metabolism and producing an aversive acetaldehyde accumulation reaction if the patient drinks. Unlike nalmefene, disulfiram requires complete abstinence from alcohol. It does not reduce craving but creates a strong negative consequence for drinking, making it most effective for highly motivated patients with structured external support.

Who Nalmefene Is Not Appropriate For

Nalmefene is not suitable for individuals who require medically supervised alcohol detox before treatment can begin. Abrupt cessation of alcohol in physically dependent patients carries risk of withdrawal seizures, delirium tremens, and autonomic instability that must be managed medically before any pharmacological craving-reduction treatment is introduced.

The following populations require careful evaluation or exclusion before nalmefene is considered:

• Patients currently using any opioid medication, including prescription pain relievers, buprenorphine, or methadone
• Patients with active psychosis, severe bipolar disorder, or recent suicidal ideation
• Patients with severe alcohol dependence requiring supervised detoxification
• Patients under age 18 (safety data not established for this population)

Treatment for Alcohol Use Disorder at Right Choice Recovery

Right Choice Recovery provides outpatient treatment for alcohol use disorder in Dayton, New Jersey, incorporating evidence-based pharmacotherapy alongside structured behavioral programming. Our intensive outpatient program supports patients who need medication management for alcohol dependence alongside individual therapy, group counseling, and relapse prevention.

Partial Care Program

The partial care program provides the highest outpatient intensity for alcohol use disorder treatment, offering medication management, CBT, DBT, and family therapy five days per week. Patients requiring MAT coordination for alcohol use disorder, including Vivitrol administration, receive medical oversight through our treatment team.

Intensive Outpatient Program

Our IOP offers morning and evening scheduling, making evidence-based alcohol use disorder treatment accessible around work and family commitments. Same-day clinical assessments are available.

References

1. European Medicines Agency. (2012). Selincro: nalmefene for reduction of alcohol consumption in adults with alcohol dependence. https://www.ema.europa.eu/
2. U.S. Food and Drug Administration. (2023). FDA approves Opvee for emergency treatment of opioid overdose. https://www.fda.gov/
3. van den Brink, W., et al. (2014). Long-term efficacy, tolerability, and safety of nalmefene as-needed in patients with alcohol dependence. European Neuropsychopharmacology, 24(9), 1432–1442.
4. Gual, A., et al. (2013). A randomized, double-blind, placebo-controlled study of nalmefene in alcohol dependence. European Neuropsychopharmacology, 23(11), 1432–1440.
5. Green, M., et al. (2024). Nalmefene hydrochloride: potential implications for treating alcohol and opioid use disorder. Substance Abuse and Rehabilitation, 15, 1–12.
6. World Health Organization. (2023). Global status report on alcohol and health. https://www.who.int/
7. Substance Abuse and Mental Health Services Administration. (2024). Medications for alcohol use disorder. https://www.samhsa.gov/
8. National Institute on Alcohol Abuse and Alcoholism. (2024). Alcohol use disorder: treatment options. https://www.niaaa.nih.gov/